<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/melinta-therapeutics-nasdaqmlnt-shares-down-11-9.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T12:56:50+00:00"/>
    <meta property="og:title" content="Melinta Therapeutics (NASDAQ:MLNT) Shares Down 11.9%"/>
    <meta property="og:description" content="Shares of Melinta Therapeutics Inc (NASDAQ:MLNT) dropped 11.9% on Tuesday . The stock traded as low as $1.55 and last traded at $1.40, approximately 7,078 shares traded hands during trading. A decline of 99% from the average daily volume of 768,142 shares. The stock had previously closed at $1.59. A number of research analysts have […]"/>
  </head>
  <body>
    <article>
      <h1>Melinta Therapeutics (NASDAQ:MLNT) Shares Down 11.9%</h1>
      <address><time datetime="2019-11-21T12:56:50+00:00">21 Nov 2019, 12:56</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/melinta-therapeutics-inc-logo.jpg"/>
      </figure>
      <p>Shares of Melinta Therapeutics Inc (NASDAQ:MLNT) dropped 11.9% on Tuesday . The stock traded as low as $1.55 and last traded at $1.40, approximately 7,078 shares traded hands during trading. A decline of 99% from the average daily volume of 768,142 shares. The stock had previously closed at $1.59.</p>
      <p>A number of research analysts have issued reports on the stock. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=MLNT">ValuEngine</a> raised shares of Melinta Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> downgraded shares of Melinta Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, HC Wainwright reiterated a “hold” rating on shares of Melinta Therapeutics in a report on Friday, October 25th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $21.30.</p>
      <p>The stock’s 50-day moving average is $3.16 and its 200 day moving average is $3.44. The stock has a market capitalization of $23.10 million, a PE ratio of -0.08 and a beta of 4.43. The company has a quick ratio of 0.72, a current ratio of 1.03 and a debt-to-equity ratio of 1.11.</p>
      <p>Melinta Therapeutics (NASDAQ:MLNT) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.55) by ($13.12). Melinta Therapeutics had a negative return on equity of 101.29% and a negative net margin of 393.39%. The business had revenue of $15.87 million during the quarter, compared to the consensus estimate of $15.51 million. As a group, equities research analysts forecast that Melinta Therapeutics Inc will post -10.01 EPS for the current year.</p>
      <p>Several institutional investors have recently modified their holdings of the company. Bank of Montreal Can raised its stake in Melinta Therapeutics by 253.2% during the 2nd quarter. Bank of Montreal Can now owns 5,503 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 3,945 shares during the last quarter. Morgan Stanley grew its holdings in shares of Melinta Therapeutics by 82.9% in the 2nd quarter. Morgan Stanley now owns 10,822 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 4,906 shares during the last quarter. Condor Capital Management bought a new stake in shares of Melinta Therapeutics in the 2nd quarter worth about $93,000. Parametric Portfolio Associates LLC bought a new stake in shares of Melinta Therapeutics in the 2nd quarter worth about $142,000. Finally, Paloma Partners Management Co bought a new stake in shares of Melinta Therapeutics in the 2nd quarter worth about $205,000. Institutional investors and hedge funds own 19.08% of the company’s stock.</p>
      <p><b>About Melinta Therapeutics</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/MLNT/">NASDAQ:MLNT</a>)</p>
      <p>Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/what-is-a-fibonacci-channel/">Fibonacci Channel</a></p>
    </article>
  </body>
</html>